5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

In December 2015, Health Canada issued a warning about a potential relationship between suicide and finasteride use and called for further research. No population based studies have assessed the risk of suicide with finasteride use, and this risk is not currently part of the product monograph. Furthermore, the link between depression and finasteride has not been well studied in the older population who are the primary users of this medication.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Treatments: 5-alpha Reductase Inhibitors

Criteria

Inclusion Criteria:

• All men >66 years of age in Ontario between 2003-2013

Exclusion Criteria:

• Non Ontario residents

• No prescriptions filled in prior 180 days

• Prior exposure to finasteride/dutasteride in the 2 years prior to study enrollment.

• Prescription initiated during hospital admission or ER visit.